Cutaneous pseudolymphoma associated with a TNF-alpha inhibitor treatment: etanercept.
Sandrine
S
Guis
Jean-Marc
JM
Schiano de Colella
Nathalie
N
Bonnet
Lucille
L
Andrac-Meyer
Nathalie
N
Balandraud
Jean-Pierre
JP
Mattei
Bernard
B
Franck
Chantal
C
Roudier
Jean
J
Roudier
Phillippe
P
Berbis
D018501:Antirheumatic Agents / Q000009:adverse effects*; D001172:Arthritis, Rheumatoid / Q000188:drug therapy*; D000068800:Etanercept; D006801:Humans; D007074:Immunoglobulin G / Q000009:adverse effects*; D008297:Male; D008875:Middle Aged; D019310:Pseudolymphoma / Q000139:chemically induced*; D018124:Receptors, Tumor Necrosis Factor; D012871:Skin Diseases / Q000139:chemically induced*; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors*
D018501:Antirheumatic Agents; D007074:Immunoglobulin G; D018124:Receptors, Tumor Necrosis Factor; D014409:Tumor Necrosis Factor-alpha; D000068800:Etanercept